Drug of abuse testing for synthetic cannabinoids and psychoactive drugs

This presentation provides an insight into synthetic cannabinoids; what they are, how they work and their mind altering impact on drug users. The presentation will take a look at the 7 major structural groups for synthetic cannabinoids and associated effects. The author will also discuss the new psychoactive substances and the evolution of these drugs in our society as well as address suitable drug testing techniques available for these products. The presentation takes a look at the features and benefits, analytical specificity, analytical selectivity and drug testing matrices. This presentation also shares which synthetic and psychoactive drugs we can currently test and provide a solution for to our stakeholders, employers and corporate customers.

Biography

Colin LaGalia is the Regional Business Director, Toxicology for the Asia Pacific, China and Japan Region, based in Singapore. He has worked extensively across the Asia Pacific, North Asia, China and Japan regions in both Corporate Commercial and Consulting roles for the past 15 years with strong established business relationships. He is responsible for providing guidance and direction on all toxicology related matters within the region, including drug and alcohol testing, product knowledge, product training and sales and marketing support and key opinion leader advocacy. He has a passion developing people capability and advocates for the importance of drug and alcohol screening to ensure safety on our roads and in our workplaces to reduce accidents and save lives. He works with the APAC Country Leaders, Toxicology Leads and the Toxicology Global Business Community to identify and develop drug and alcohol testing policies and procedures at government, police and corporate levels.

Colin.LaGalia@alere.com

Notes: